Skip to content

Olarib

Generic Name
Olaparib
Therapeutic Area
Oncology
Therapeutic Class
PARP inhibitors (poly ADP-ribose polymerase inhibitors). It is a type of targeted cancer therapy and an antineoplastic agent.
Dosage Form
Tablets
Strength
150 mg
Pack Size
60’s
Registration Number
129294

Overview

Olaparib is an oral targeted therapy belonging to the PARP inhibitor class. It blocks enzymes involved in DNA repair, particularly in cancer cells with BRCA1/BRCA2 mutations and certain other DNA repair deficiencies. It is used in selected treatment settings for ovarian, breast, pancreatic and prostate cancers.

Indication

Treatment of certain types of ovarian, breast, pancreatic, and prostate cancers, often in patients with specific genetic mutations (such as BRCA1/2) or homologous recombination repair (HRR) gene mutations.